This site is intended for health professionals only

Preventing seizures


UCB today announced new findings for Vimpat® (lacosamide) that offer additional support regarding the long-term benefits of the anti-epileptic drug (AED) as an adjunctive therapy for adults with uncontrolled partial-onset seizures.

“These data add to the growing body of support showing that Vimpat® reduces seizure frequency and improves patient-reported quality of life measures on a long-term basis,” said Aatif Husain, MD, lead author of one of the studies and Director, Clinical Neurophysiology Training Program, Duke University Medical Center.

“These results, combined with the consistent long-term tolerability profile, are important milestones for this AED.”

An open-label extension study analysed patient-reported outcomes and found that, after a year of treatment with Vimpat®, patients reported significant improvements in all aspects of seizure severity and across almost all health-related quality of life (HRQoL) assessments, including social functioning and emotional well-being.

Results of this open-label extension study demonstrated sustained efficacy in adults taking Vimpat® as adjunctive therapy up to five years, and a long-term tolerability profile consistent with that of previous Vimpat® trials.

These and other Vimpat® data were presented at the 64th annual meeting of the American Epilepsy Society (AES) in San Antonio, Texas.

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine